FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
ional study at 3 German sites. All participants underwent thorough neurological examination, nerve conduction studies, quantitative sensory testing, and skin biopsies to assess intraepidermal nerve…
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Key Points. The cumulative incidence of SCNSL was 2.6% at two years with death and relapse without CNS involvement as competing risksThe most significant p
An abstract is unavailable.
Key Points. Chemo conditioning with busulfan- or treosulfan-based regimens yields comparable outcomes for allo-HSCT in children with ALL.Either regimen can
Blood | 144 | 22 | November 2024
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…
PAIN publishes research on the nature, mechanisms and treatment of pain. The journal provides a forum for the dissemination of research in the basic and…